Crinetics Pharmaceuticals(CRNX) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of First Drug Candidate from a Novel Nonpeptide Drug Conjugate Platform at North American Neuroendocrine Tumor Society (NANETS) Total of Four New Drug Candidates in IND Enabling Preclinical Studies Management Hosting Conference Call at 4:30 p.m. ET To ...